Q
QuantAbundance

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

31,229 signal articles · 0 in last 24h · 160,153 total before filter · latest 1d ago
0last 24h
599last 7d
87● bullish (7d)
64● bearish (7d)
214publishers
AllMacro110Earnings164M&A62Regulatory12Product10Analyst17
✕ clear all filterssentiment: bullishSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
This Week In Cloud AI - AI Spending Soars Worldwide As Industries Transform
Simply Wall St.64d agobullish
This Week In Cloud AI - AI Spending Soars Worldwide As Industries Transform

In its first year, BCC Research's Artificial Intelligence vertical has developed a comprehensive suite of reports to provide a detailed view of the global AI market. This collection includes quarterly Core Four reports alongside monthly Pulse Reports and an AI Sentiment Index, offering insights into AI adoption, disruption, usage, and investment across various industries worldwide. Notably, the reports highlight a structural shift in industries such as finance, logistics, and digital health,...

2 ‘Strong Buy’ IPO Stocks JPMorgan Thinks Are Worth Watching
TipRanks64d agobullish
2 ‘Strong Buy’ IPO Stocks JPMorgan Thinks Are Worth Watching

The IPO market has made an impressive comeback this year. Momentum began building in the first quarter and accelerated in the second, with traditional IPOs raising $114.1 billion through June 30, 2026 – roughly seven times the amount raised during the first half of 2025. SpaceX, the largest IPO in Wall Street history, understandably dominated the headlines and made Elon Musk the world’s first trillionaire, but the strength of the market extended well beyond a single blockbuster listing.Claim 55%

AbbVie Bought Apogee to Strengthen Its Portfolio. Now It’s Cutting Earnings Guidance.
Barrons.com64d agobullish
AbbVie Bought Apogee to Strengthen Its Portfolio. Now It’s Cutting Earnings Guidance.

AbbVie shares took a hit Friday after costs related to the drugmaker’s acquisition of Apogee Therapeutics forced a cut to its full-year profit outlook. Second-quarter revenue jumped 10% to nearly $17 billion, beating the $16.8 billion consensus estimate among analysts polled by FactSet. AbbVie posted adjusted earnings of $3.65 a share, narrowly ahead of Wall Street’s call for $3.60.

Tempo Brings BlackRock’s BUIDL to Businesses in New Treasury Partnership
CoinGape64d agobullish
Tempo Brings BlackRock’s BUIDL to Businesses in New Treasury Partnership

The ongoing race to become the blockchain of choice for institutional finance is increasingly shifting beyond stablecoins to tokenized Treasury products. The latest entrant is Stripe’s blockchain Tempo, which has integrated BlackRock’s USD Institutional Digital Liquidity Fund (BUIDL) into its ecosystem. It gives eligible users access to the world’s largest tokenized money market fund and

Moderna Earnings Are Better Than Expected So Why Is the Stock Falling?
Barrons.com64d agobullish
Moderna Earnings Are Better Than Expected So Why Is the Stock Falling?

Moderna posted a narrower per-share loss and higher revenue in its latest quarter, but shares were tumbling anyway. Moderna posted a loss of $1.97 a share, narrower than the loss of $2.01 Wall Street had anticipated, and slimmer than the per-share loss of $2.13 reported last year. The drugmaker reiterated its full-year guidance of 10% revenue growth, evenly split between U.S. and international sales.